NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

Approval is likely, the cost and benefit are very favorable at that rate.

The company will be well positioned to advance the treatment and reduce their costs as well. They are well positioned. The discussions I have had with AI, based on the most recent results with combinations, suggests that they would qualify yes, for premium pricing even in the UK. So their current pricing fits well within that range, but I know that they may want to make it less expensive. My suggestion is that they maintain a reasonable comparative price to where they are now or above, for patients who are covered, so that they can provide lower prices to patients who need treatment and do not have coverage. They need to ensure that the company is on solid financial grounds before they can pursue their best impulses.